Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary aim of this study is to assess the effect of hyperoncotic albumin on vascular hemodynamics and oxygen delivery after orthotopic liver transplant. The secondary aim is to try to identify the dominant physiological mechanism so that we will be able to better identify patients that may benefit from the use of albumin (25%) boluses in addition to standard care in patients following liver transplantation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Saline | Active Comparator |
| |
| 25% albumin | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Saline | Drug | 100 ml of saline will be given in addition to the standard of care every 8 hours for 24 hours. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cardiac index (CI) | 60 minutes after the infusion of the fluid |
| Measure | Description | Time Frame |
|---|---|---|
| Cardiac function response | An improvement in Q due primarily to a change in cardiac function should have an increase in Q of ≥ 0.3 ml/min/m2/mmHg | 30 and 60 minutes after the infusion of the fluid |
| A decrease in leak and plasma expansion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sheldon Magder, MD | Contact | 514-934-1934 | 35253 | sheldon.magder@muhc.mcgill.ca |
| Thomas Lescot, MD, PhD | Contact | 514-934-1934 | 36736 | thomas.lescot@mail.mcgill.ca |
| Name | Affiliation | Role |
|---|---|---|
| Sheldon Magder, MD | McGill University Health Centre/Research Institute of the McGill University Health Centre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal Victoria Hospital | Montreal | Quebec | H3A1A1 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 25% albumin | Drug | 100 ml of 25% albumin will be given in addition to the standard of care every 8 hours for 24 hours |
|
A decrease in leak and plasma expansion will be determined by the Harrison formula for calculating a change in plasma volume from the change in Hb and change in Hct
| 30 and 60 minutes after the infusion of the fluid |
| Cardiac output response | Cardiac output response primarily due to a "volume effect" would be expected to have an increase of CVP of a minimum of 2 mmHg and an increase in CI of > 0.3 L/min/m2 per mmHg. | 30 and 60 minutes after the infusion of the fluid |
| Detoxification effect of albumin | A increase in vascular tone will be identified by an increase in systemic vascular resistance or a rise in blood pressure without a change in cardiac output or a rise in blood pressure with a fall in cardiac output | 30 and 60 minutes after infusion |
| ID | Term |
|---|---|
| D012965 | Sodium Chloride |
| D000418 | Albumins |
| ID | Term |
|---|---|
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided